BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

Covaxx licenses COVID vaccine to Aurobindo Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) gained exclusive rights from the Covaxx unit of United Biomedical Inc. to develop and market UB-612 in India...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

Russian and AZ COVID vaccines in combo trialAstraZeneca plc (LSE:AZN; NASDAQ:AZN) will begin by year-end a clinical trial of its AZD1222, developed with the University of Oxford, in combination with the adenovirus serotype 26 (Ad26)...
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

Three-month immunity data for Moderna, NIH COVID vaccineNIH reported in The New England Journal of Medicine that all 34 Phase I subjects who received two doses of 100 ug mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) 28 days apart had...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

A deal with Lilly delivering $135 million up front will allow Precision BioSciences to derive immediate value from the in vivo gene correction application of its ARCUS platform, which has lagged its clinical pipeline of...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

In the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy test, growing the number of genetic biomarkers indicated for matching patients to targeted therapies. The...
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

With $107 million in fresh series A cash, gene therapy company AavantiBio will develop a program for Friedreich’s ataxia with leadership joining from Sarepta, which joined the A round. Co-founded by a pair of gene...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

DISEASE CATEGORY: Pulmonary INDICATION: Cystic fibrosis (CF) A small molecule inhibitor of four kinases that regulate splicing could treat CF caused by the most common disease-associated CFTR splicing...
Items per page:
1 - 10 of 644
BioCentury | Feb 26, 2021
Deals

Feb. 25 Quick Takes: AveXis execs, Deerfield launch Jaguar plus one; Sarepta DMD approval, Apollomics IPO plans and Sirion-Sanofi, an Oxford pair and DeuterOncology

Led by Sean Nolan as executive chairman and Joe Nolan as CEO, the former management team of AveXis partnered with Deerfield Management to launch Jaguar Gene Therapy LLC. Jaguar’s preclinical pipeline of AAV9-based gene therapies...
BioCentury | Feb 4, 2021
Deals

Feb. 3 Quick Takes: Hillhouse takes stakes in InnoCare, Luye; plus Merck KGaA, Inivata, Reverie, Neurocrine, Eisai and more

InnoCare Pharma Ltd. (HKEX:9969) raised HK$3 billion ($392 million) through the sale of 210.5 million shares at HK$14.45 to Hillhouse, which purchased 191.6 million shares for a 12.77% stake in the cancer and autoimmune company,...
BioCentury | Jan 1, 2021
Regulation

Another year of firsts in FDA’s new drug approvals

The COVID-19 pandemic didn’t stand in the way of new drug approvals by FDA in 2020, but few new modalities crossed the finish line despite the clinical development fervor around platform technologies and...
BioCentury | Dec 31, 2020
Deals

Dec. 30 Quick Takes: COVAXX-Aurobindo and Moderna-Recipharm in COVID deals; plus United-Y-mAbs, Zai-Cullinan and Incyte-Cellenkos

Covaxx licenses COVID vaccine to Aurobindo Aurobindo Pharma Ltd. (NSE:AUROPHARMA; BSE:524804) gained exclusive rights from the Covaxx unit of United Biomedical Inc. to develop and market UB-612 in India...
BioCentury | Dec 12, 2020
Product Development

Dec. 11 Quick Takes: AZ to run combo trial with Sputnik; plus Phase III hits for Lilly, AbbVie and TG, data from Immutep, NVS, Mycovia, Sarepta and Greenwich

Russian and AZ COVID vaccines in combo trialAstraZeneca plc (LSE:AZN; NASDAQ:AZN) will begin by year-end a clinical trial of its AZD1222, developed with the University of Oxford, in combination with the adenovirus serotype 26 (Ad26)...
BioCentury | Dec 4, 2020
Product Development

Dec. 3 Quick Takes: Moderna, NIH tout persisting neutralizing antibodies from COVID vaccine; plus Bayer, Galapagos, Braeburn, J&J and Equillium

Three-month immunity data for Moderna, NIH COVID vaccineNIH reported in The New England Journal of Medicine that all 34 Phase I subjects who received two doses of 100 ug mRNA-1273 from Moderna Inc. (NASDAQ:MRNA) 28 days apart had...
BioCentury | Nov 20, 2020
Deals

After three-target Lilly deal, Precision BioSciences hunting for more partnerships

A deal with Lilly delivering $135 million up front will allow Precision BioSciences to derive immediate value from the in vivo gene correction application of its ARCUS platform, which has lagged its clinical pipeline of...
BioCentury | Nov 10, 2020
Regulation

Label expansions coming at a rapid clip for Foundation’s blood-based companion cancer diagnostic

In the past three weeks, FDA has added four companion diagnostic indications to the label of Foundation Medicine’s liquid biopsy test, growing the number of genetic biomarkers indicated for matching patients to targeted therapies. The...
BioCentury | Oct 23, 2020
Finance

Sarepta joins investor trio in Aavanti’s $107M series A round to develop gene therapy for Friedreich’s ataxia

With $107 million in fresh series A cash, gene therapy company AavantiBio will develop a program for Friedreich’s ataxia with leadership joining from Sarepta, which joined the A round. Co-founded by a pair of gene...
BioCentury | Sep 29, 2020
Distillery Therapeutics

Small molecule kinase inhibitor for cystic fibrosis with splicing mutation

DISEASE CATEGORY: Pulmonary INDICATION: Cystic fibrosis (CF) A small molecule inhibitor of four kinases that regulate splicing could treat CF caused by the most common disease-associated CFTR splicing...
Items per page:
1 - 10 of 644